SCHEMBL20916643

SCHEMBL20916643

CC(C)Cc1c(C(=O)N2CCC2)c(Cl)cc2[nH]ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
P2RX7 Q99572 3/20 0.39
SPR P35270 1/20 0.38
HRH4 Q9H3N8 5/20 0.38
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.37
GLA P06280 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKAG3 Q9UGI9 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20916549 0.74 GAA (0.43) GAAMAPTP2RX7SPRHRH4
SCHEMBL20916669 0.71 HRH4 (0.41) GAAMAPTHRH4KMT2APRKAB2
SCHEMBL20916635 0.69 MAPT (0.32) MAPT
SCHEMBL20916603 0.69 PIK3CA (0.33) SPR
SCHEMBL20916459 0.69 DPP4 (0.37) SPRHPGDNPC1MEN1KMT2A
SCHEMBL20916676 0.68 AKT1 (0.37) MAPT
SCHEMBL15797442 0.62 P2RX7 (0.51) P2RX7HPGDALDH1A1PRKAB2PRKAG1
SCHEMBL15797610 0.60 P2RX7 (0.50) P2RX7LMNASMN1; SMN2
SCHEMBL3549054 0.59 HRH4 (0.52) HRH4HPGDMEN1LMNAKMT2A
SCHEMBL22216445 0.59 MAPK14 (0.64) MAPTLMNAGHSRMAPK14CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793551-B2 Benzimidazole-indole inhibitors of Mnk1 and Mnk2 Effector Therapeutics Inc. (US) 2020-10-06 US disclosed
US-10793551-B2 Benzimidazole-indole inhibitors of Mnk1 and Mnk2 Effector Therapeutics Inc. (US) 2020-10-06 US disclosed
EP-3697777-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 eFFECTOR Therapeutics, Inc. (US) 2020-08-26 EP disclosed
WO-2019079369-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (US) 2019-04-25 WO disclosed
WO-2019079369-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (US) 2019-04-25 WO disclosed
US-20190119256-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (JP) 2019-04-25 US disclosed
US-20190119256-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (JP) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119256-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 NEK5, MINK1, NIM1K GAA 4425/4885MAPT 553/4885P2RX7 1479/4885
US-10793551-B2 Benzimidazole-indole inhibitors of Mnk1 and Mnk2 NEK5, MINK1, NIM1K GAA 4425/4885MAPT 553/4885P2RX7 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.